Report stresses Chinese need for enhanced cancer drug innovation and access
A member association representing pharma companies investing in China has stressed how far they and other researchers have come in reducing cancer mortality rates, but also how far there is to go in tackling the huge burden of the disease.
The R&D Based Pharmaceutical Association Committee of the China Association of Enterprises together with Foreign Investment (RDPAC) represents 38 companies including 21 from Europe, 11 from the USA and six from Japan.
It has released a report titled Faces of Innovation: Meeting the Challenge of Cancer in Guangzhou, which outlines the cost of cancer to China and the wider world, and the potential benefits of enhancing innovation and improving drug access in extending patient life expectancy, improving quality of life and reducing the burden of disease on society.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze